Credit Suisse’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-69,928
| Closed | -$1.3M | – | 3192 |
|
|
2023
Q3 | $1.3M | Sell |
69,928
-89,828
| -56% | -$1.02M | ﹤0.01% | 2121 |
|
|
2023
Q2 | $1.77M | Buy |
159,756
+32,793
| +26% | +$457K | ﹤0.01% | 1993 |
|
|
2023
Q1 | $1.71M | Sell |
126,963
-19,247
| -13% | -$333K | ﹤0.01% | 1978 |
|
|
2022
Q4 | $1.81M | Buy |
146,210
+43,933
| +43% | +$622K | ﹤0.01% | 1942 |
|
|
2022
Q3 | $1.43M | Sell |
102,277
-357
| -0.3% | -$5.75K | ﹤0.01% | 2070 |
|
|
2022
Q2 | $1.42M | Sell |
102,634
-1,106
| -1% | -$17.7K | ﹤0.01% | 2143 |
|
|
2022
Q1 | $1.69M | Buy |
103,740
+7,576
| +8% | +$119K | ﹤0.01% | 2202 |
|
|
2021
Q4 | $1.57M | Buy |
96,164
+32,212
| +50% | +$543K | ﹤0.01% | 2974 |
|
|
2021
Q3 | $950K | Sell |
63,952
-733
| -1% | -$11.7K | ﹤0.01% | 3388 |
|
|
2021
Q2 | $1.29M | Sell |
64,685
-19,986
| -24% | -$396K | ﹤0.01% | 3188 |
|
|
2021
Q1 | $1.95M | Sell |
84,671
-46,942
| -36% | -$1.31M | ﹤0.01% | 2836 |
|
|
2020
Q4 | $3.25M | Sell |
131,613
-6,352
| -5% | -$210K | ﹤0.01% | 2438 |
|
|
2020
Q3 | $5.72M | Buy |
137,965
+9,816
| +8% | +$451K | ﹤0.01% | 1706 |
|
|
2020
Q2 | $6.14M | Sell |
128,149
-72,201
| -36% | -$5.58M | ﹤0.01% | 1578 |
|
|
2020
Q1 | $12.6M | Buy |
200,350
+67,035
| +50% | +$6.02M | 0.01% | 1065 |
|
|
2019
Q4 | $16.5M | Sell |
133,315
-23,144
| -15% | -$2.07M | 0.01% | 1140 |
|
|
2019
Q3 | $10.4M | Sell |
156,459
-47,969
| -23% | -$3.22M | 0.01% | 1288 |
|
|
2019
Q2 | $16.3M | Buy |
204,428
+93,726
| +85% | +$8.39M | 0.01% | 1040 |
|
|
2019
Q1 | $12.4M | Sell |
110,702
-6,298
| -5% | -$688K | 0.01% | 1119 |
|
|
2018
Q4 | $11.8M | Buy |
117,000
+13,799
| +13% | +$1.43M | 0.01% | 1070 |
|
|
2018
Q3 | $13M | Sell |
103,201
-19,360
| -16% | -$2.05M | 0.01% | 1104 |
|
|
2018
Q2 | $10.3M | Sell |
122,561
-40,470
| -25% | -$2.96M | 0.01% | 1227 |
|
|
2018
Q1 | $10M | Buy |
163,031
+7,374
| +5% | +$444K | 0.01% | 1238 |
|
|
2017
Q4 | $9.09M | Sell |
155,657
-36,526
| -19% | -$2.3M | 0.01% | 1344 |
|
|
2017
Q3 | $11.2M | Buy |
192,183
+44,578
| +30% | +$4.8M | 0.01% | 1182 |
|
|
2017
Q2 | $17.9M | Sell |
147,605
-39,736
| -21% | -$4.6M | 0.02% | 863 |
|
|
2017
Q1 | $21.2M | Buy |
187,341
+36,368
| +24% | +$4.25M | 0.02% | 808 |
|
|
2016
Q4 | $16.4M | Buy |
150,973
+10,407
| +7% | +$1.24M | 0.02% | 914 |
|
|
2016
Q3 | $23.1M | Buy |
140,566
+56,926
| +68% | +$8.97M | 0.02% | 746 |
|
|
2016
Q2 | $11.9M | Buy |
83,640
+9,859
| +13% | +$1.44M | 0.01% | 1045 |
|
|
2016
Q1 | $9.48M | Buy |
73,781
+14,514
| +24% | +$1.71M | 0.01% | 1142 |
|
|
2015
Q4 | $8.85M | Buy |
59,267
+4,343
| +8% | +$735K | 0.01% | 1221 |
|
|
2015
Q3 | $9.11M | Sell |
54,924
-20,833
| -27% | -$4.58M | 0.01% | 1170 |
|
|
2015
Q2 | $18.3M | Buy |
75,757
+10,317
| +16% | +$2.75M | 0.02% | 886 |
|
|
2015
Q1 | $18.5M | Buy |
65,440
+9,324
| +17% | +$2.02M | 0.02% | 853 |
|
|
2014
Q4 | $8.75M | Buy |
56,116
+17,488
| +45% | +$3.23M | 0.01% | 1373 |
|
|
2014
Q3 | $9.14M | Buy |
38,628
+16,899
| +78% | +$4.31M | 0.01% | 1347 |
|
|
2014
Q2 | $5.14M | Buy |
21,729
+7,212
| +50% | +$1.9M | ﹤0.01% | 1939 |
|
|
2014
Q1 | $4.79M | Buy |
14,517
+9,624
| +197% | +$3.25M | ﹤0.01% | 1805 |
|
|
2013
Q4 | $334K | Buy |
+4,893
| New | +$283K | ﹤0.01% | 4004 |
|
Credit Suisse's ICPT Position: Q4 2023 in Review
Credit Suisse sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 69,928 shares — an estimated $1.3M sold.
Credit Suisse first reported a position in ICPT in Q4 2013 and held it in 40 quarters. The position peaked at $23.1M in Q3 2016. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Credit Suisse reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Credit Suisse sold 69,928 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $1.3M.
- Credit Suisse first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 40 quarters.
- Credit Suisse's Intercept Pharmaceuticals, Inc. position peaked at $23.1M in Q3 2016.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.